Kinetics, Biodistribution, Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit, in Healthy Male Volunteers and Patients With Limited Recurrent Prostate Cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Prostatic Neoplasm
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Enrollment
- 3
- Locations
- 1
- Primary Endpoint
- Maximum Plasma concentration
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
Prostate cancer is the most common cancer in men. Early detection of primary diseases and recurrence is crucial for patient counseling and management. Conventional imaging modalities (CT-MRI) are limited to detect recurrence.
Choline-based PET/CT is currently widely used as primary staging tool in prostate cancer and in patients with suspicious recurrent disease.
Compared to choline-based tracers, 68Ga-PSMA ligands have been shown to have a higher diagnostic efficacy and to increase the detection of metastases even at low PSA levels. The most widely used prostate-specific membrane antigen (PSMA) ligand is PSMA-11. A supplier, ANMI, has developed a kit formulation of PSMA-11 which will be test in this clinical trial.
Detailed Description
Prostate cancer represents the most common cancer in men and accounts for the third most common cancer death in men. Up to 50% of all patients undergoing radical prostatectomy or radiotherapy for primary treatment of prostate cancer develop biochemical recurrence. Early detection of primary diseases and recurrence is crucial for patient counseling and management. Conventional imaging modalities such as computed tomography (CT) or magnetic resonance imaging (MRI) are limited because they focus on morphologic information such as lymph node size and tissue structure. Positron emission tomography/computed tomography (PET/CT) is a hybrid imaging technique combining functional and morphological information. Choline-based PET/CT is currently widely used as primary staging tool in prostate cancer and in patients with suspicious recurrent disease. Compared to choline-based tracers, 68Ga-PSMA ligands have been shown to have a higher diagnostic efficacy and to increase the detection of metastases even at low PSA levels. The most widely used prostate-specific membrane antigen (PSMA) ligand is PSMA-11. A supplier, ANMI, has developed a kit formulation of PSMA-11 which can be labeled at room temperature by direct incubation of the kit with the gallium-68 eluted from a 68Ge/68Ga generator.
Investigators
Eligibility Criteria
Inclusion Criteria
- •For all individuals
- •Male gender
- •Normal renal function (MDRD glomerular filtration rate \>60/ml/min/1.73m2)
- •Normal liver function (bilirubin, alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and gamma glutamyltransferase \[GGT\] \<2x upper limit of normal \[ULN\]
- •Normal bone marrow function (hemoglobin \[Hb\]\>12g/dl, white blood cells \[WBC\]\>4500/µl, platelets\>140,000/µl)
- •Informed consent For patients with limited recurrent prostate cancer
- •≥18 years of age
- •Radical therapy by surgery or radiotherapy
- •Prostate specific antigen \[PSA\] level between 0.5 and 2ng/ml confirmed within two weeks before inclusion
- •Negative or inconclusive findings with standard imaging techniques as assessed by the referring physician with e.g. thoraco-abdominal Computed Tomography \[CT\] scan, bone scan or Magnetic Resonance Imaging \[MRI\] within the previous two months before inclusion
Exclusion Criteria
- •For all individuals
- •Urinary incontinence
- •Chronic renal disease (except nephroangiosclerosis or early diabetic nephropathy) even if renal function is normal
- •Concomitant malignant disease or diagnosis of cancer within five years prior to enrollment (except basal cell carcinoma)
- •History of salivary gland disease (except recovered childhood mumps)
- •History of surgery or radiotherapy of the salivary gland or neck
- •Medical or psychiatric condition that would preclude the conduct of the study to its end
- •Pregnant partner
Outcomes
Primary Outcomes
Maximum Plasma concentration
Time Frame: at day 0
Measures based on blood tests
Maximum Urine concentration
Time Frame: Up to 6 months
Based on urine samples
Secondary Outcomes
- Time dependant changes of the injected activity per organ(at day 0)
- Incidence of treatment emergent adverse events(Up to 6 months)